Vitamin E

• Correcting documented vitamin E deficiency (rare)
• Repletion in fat-malabsorption disorders (cystic fibrosis, cholestatic liver disease, Crohn's, short-bowel)
• Treating abetalipoproteinemia (very high oral doses)
• Managing ataxia with vitamin E deficiency (AVED), a genetic transfer-protein disorder
• One component of the AREDS/AREDS2 formula for slowing progression of intermediate age-related macular degeneration
• Dietary intake from nuts, seeds, and vegetable oils (preferred over supplements)

Vitamin E refers to a family of eight related fat-soluble compounds rather than a single molecule, four tocopherols (alpha, beta, gamma, delta) and four tocotrienols (alpha, beta, gamma, delta), distinguished by methyl group positions on the chromanol ring and saturation of the phytyl tail. Alpha-tocopherol is the most extensively characterized form and the only form maintained at substantial plasma concentrations through selective hepatic recognition by alpha-tocopherol transfer protein (alpha-TTP); other forms have less hepatic retention and reach lower plasma concentrations despite similar dietary intake. This biology has substantial implications for supplementation strategy: high-dose alpha-tocopherol supplementation can paradoxically displace gamma-tocopherol and other family members from plasma and tissues, producing potentially unfavorable redistribution of the vitamin E family. Modern research interest in "mixed tocopherols" (alpha + gamma + delta combinations) and tocotrienols reflects awareness that isolated alpha-tocopherol supplementation may not capture the full physiological vitamin E spectrum. The natural-versus-synthetic distinction is biologically significant. Natural vitamin E (d-alpha-tocopherol, with R-configuration at all three chiral centers) is the form synthesized by plants and incorporated into food. Synthetic vitamin E (dl-alpha-tocopherol, often labeled "all-rac-alpha-tocopherol") is a racemic mixture of all eight possible stereoisomers; alpha-TTP preferentially binds the R-isomers, so synthetic vitamin E has substantially lower biological activity per mg than natural. The IOM/USP convention assigns 1 IU = 0.67mg d-alpha-tocopherol (natural) or 1mg dl-alpha-tocopherol (synthetic), synthetic vitamin E requires approximately 1.36-fold higher mg dose for equivalent biological activity. Esterified forms (tocopheryl acetate, tocopheryl succinate, tocopheryl phosphate) provide enhanced storage stability and are hydrolyzed to free tocopherol upon absorption. The annatto-derived tocotrienol category (from Bixa orellana, the achiote tree) provides essentially pure delta- and gamma-tocotrienols without alpha-tocopherol, emerging interest for cardiovascular and neuroprotective applications distinct from classical alpha-tocopherol supplementation. The pharmacology centers on lipid-soluble antioxidant function, interception of peroxyl radicals (ROO•) in cell membranes through hydrogen donation from the chromanol hydroxyl group, producing a tocopheroxyl radical that is regenerated by vitamin C, glutathione (selenium-dependent), and other components of the cellular antioxidant network. The selenium-vitamin E partnership documented by Klaus Schwarz at NIH in 1957, the foundational "factor 3" liver necrosis prevention work that established selenium essentiality, reflects the integrated biology: vitamin E intercepts peroxyl radicals in lipid environments; selenium-dependent glutathione peroxidases reduce the lipid hydroperoxides that form despite alpha-tocopherol activity; the system is functionally inseparable. The clinical evidence base has been substantially recalibrated by major prevention trials. The ATBC trial (Alpha-Tocopherol Beta-Carotene Cancer Prevention 1994 in Finnish smokers) showed no lung cancer benefit and increased hemorrhagic stroke risk; the HOPE trial (2000 Lancet) showed no cardiovascular protective effect; the Heart Protection Study (2002 Lancet) confirmed null cardiovascular outcomes; the SELECT trial (2009 JAMA) demonstrated possible increased prostate cancer risk with synthetic alpha-tocopherol 400 IU/day. Miller 2005 Annals of Internal Medicine meta-analysis suggested possible increased all-cause mortality at chronic high-dose vitamin E supplementation (>400 IU/day). The cumulative recalibration represents one of the most significant mechanism-translation failures in nutritional pharmacology, substantial mechanistic plausibility (lipid peroxidation prevention, oxidative stress reduction) did not translate to clinical outcome benefit and may have produced harm at high doses in some populations. Modern vitamin E supplementation guidance has substantially recalibrated toward AI-level intake (15mg/day) from food sources rather than high-dose pharmacological supplementation.

Standard vitamin E intake aims at the AI of 15mg/day adult (22 IU natural d-alpha-tocopherol; 33 IU synthetic dl-alpha-tocopherol). The Upper Limit (UL) is 1000mg/day (1500 IU natural; 2200 IU synthetic), substantially higher than RDA reflects historical safety positioning, but current evidence supports much lower practical ceiling. Miller 2005 meta-analysis suggested possible increased all-cause mortality at chronic supplementation above 400 IU/day; SELECT trial concerning prostate cancer signal at 400 IU/day; ATBC hemorrhagic stroke signal at 50mg/day in smokers. The practical guidance has substantially recalibrated toward AI-level dietary intake from whole foods rather than high-dose pharmacological supplementation. Vegetable oils (wheat germ oil, sunflower oil, safflower oil), nuts (almonds, hazelnuts, sunflower seeds), avocados, and leafy greens provide reliable dietary vitamin E. Take supplementation with food containing fat, vitamin E is fat-soluble and absorption substantially improves with lipid co-administration. The natural d-alpha-tocopherol form is preferred over synthetic dl-alpha-tocopherol given superior alpha-TTP recognition; mixed tocopherol products provide broader family supplementation; annatto-derived tocotrienol products provide specialty alpha-tocopherol-free tocotrienol supplementation. For specific clinical applications: Sano 1997 Alzheimer's used 2000 IU/day (specialist coordination); PIVENS 2010 NAFLD used 800 IU/day (hepatology coordination); AREDS protocol uses 400 IU as part of antioxidant cocktail (ophthalmology). Routine consumer supplementation should generally not exceed 400 IU/day given Miller and SELECT evidence. The selenium-vitamin E integration through Schwarz 1957 foundational work and ongoing antioxidant biology supports comprehensive antioxidant nutrition planning; but the SELECT trial demonstrated the combination at high doses (200mcg selenium + 400 IU vitamin E) did not produce cancer prevention benefits and produced concerning signals. Pre-surgical discontinuation 2 weeks reasonable; coordinate with prescribing physician for users on anticoagulants. The pregnancy AI (15mg/day) is the same as non-pregnant adult; high-dose pregnancy supplementation has been associated with possible adverse outcomes in preliminary research. Pediatric AIs are age-specific (6mg ages 1-3, 7mg ages 4-8, 11mg ages 9-13, 15mg adolescents).

Adult AI

15mg/day (22 IU natural, 33 IU synthetic)

Lactation AI

19mg/day

Pregnancy AI

15mg/day

Adolescent AI

15mg/day

Upper Limit (UL) adult

1000mg/day (1500 IU natural)

Mortality signal threshold (Miller 2005)

>400 IU/day chronic

Conversion: natural to IU

1mg = 1.49 IU d-alpha-tocopherol

Conversion: synthetic to IU

1mg = 1 IU dl-alpha-tocopherol

• d-Alpha-Tocopherol (Natural, Single Isomer)

  Rating: gold

  The single-isomer natural form (R,R,R configuration) with highest biological activity. Preferred form for vitamin E supplementation given superior alpha-TTP recognition and tissue retention. Major supplement brands (NOW Foods, Pure Encapsulations, Thorne, Designs for Health, Solgar) provide d-alpha-tocopherol products at 100-400 IU range. Premium pricing relative to synthetic forms but biologically warranted.

• dl-Alpha-Tocopherol (Synthetic, All-Rac)

  Rating: good

  Synthetic racemic mixture of 8 stereoisomers, only the R,R,R isomer has full alpha-TTP recognition. Requires approximately 1.36x higher mg dose for equivalent biological activity. Substantially less expensive than natural form. Used in many older clinical trials including ATBC. Used in many mass-market multivitamin products at modest doses.

• Mixed Tocopherols (Alpha + Beta + Gamma + Delta)

  Rating: gold

  Comprehensive tocopherol family supplementation reflecting broader vitamin E spectrum than alpha-tocopherol alone. Mechanistically reasonable for users seeking comprehensive antioxidant support; preliminary evidence suggests gamma-tocopherol has distinct anti-inflammatory effects through different mechanism. Premium pricing reflecting comprehensive composition.

• Tocotrienols (Annatto-Derived)

  Rating: gold

  Tocotrienols are unsaturated vitamin E family members with substantially different biology from tocopherols. Annatto-derived tocotrienols (from Bixa orellana achiote) provide alpha-tocopherol-free tocotrienol supplementation (delta- and gamma-tocotrienols dominant). Emerging cardiovascular and neuroprotective evidence; less established than tocopherol evidence base. Premium pricing reflecting specialized chemistry.

• Tocopheryl Acetate (Esterified Storage Form)

  Rating: good

  Esterified vitamin E with enhanced storage stability, hydrolyzed to free tocopherol upon absorption. Used in most multivitamin formulations and cosmetic products. Pharmacologically equivalent to free tocopherol once absorbed. Acceptable for most supplementation applications.

• Tocopheryl Succinate (Vitamin E Succinate)

  Rating: good

  Succinate ester form with some preliminary evidence for distinct cancer biology effects beyond simple tocopherol metabolism. Less common in consumer supplements; some specialty cancer-prevention positioning. Effect-size evidence preliminary.

• Vitamin E + C + Selenium Combinations

  Rating: good

  Common antioxidant family combinations reflecting integrated antioxidant biology (vitamin E + vitamin C + selenium). The SELECT trial used the vitamin E + selenium combination with concerning prostate cancer signal at high doses. Reasonable comprehensive antioxidant supplementation at AI doses; caution about chronic high-dose combinations given SELECT and Miller meta-analysis findings.

• Whole Food Vitamin E (Wheat Germ Oil, Sunflower Seeds, Almonds)

  Rating: gold

  Dietary vitamin E from wheat germ oil (highest concentration, 150mg/100g), sunflower seeds (~35mg/100g), almonds (~25mg/100g), hazelnuts, avocados, leafy greens. The most reliable foundation for vitamin E status. Whole food sources provide vitamin E in the context of complementary phytonutrients and natural lipid carriers.

• High-Dose Vitamin E (>400 IU/day)

  Rating: caution

  Doses above 400 IU/day chronic supplementation are associated with Miller 2005 meta-analysis modest mortality signal, SELECT trial possible prostate cancer signal, and ATBC trial hemorrhagic stroke signal. Routine high-dose chronic supplementation in healthy users is not warranted; specific clinical applications (Alzheimer's disease per Sano protocol, others) under specialist coordination.

• Documented vitamin E deficiency (rare in modern populations)

  Strength of evidence for this group: strong

  True vitamin E deficiency is uncommon in modern populations, typically associated with fat malabsorption syndromes (cystic fibrosis, abetalipoproteinemia, cholestatic liver disease), prolonged TPN without vitamin E, or specific genetic conditions (ataxia with vitamin E deficiency AVED, alpha-TTP mutations). Documented deficiency warrants supplementation under specialist coordination.

• Cystic fibrosis and fat malabsorption

  Strength of evidence for this group: strong

  Fat malabsorption substantially impairs vitamin E absorption. Standard CF management includes fat-soluble vitamin supplementation (A, D, E, K). Specialist CF clinic coordination essential.

• Alzheimer's disease (specialist application)

  Strength of evidence for this group: cautious

  Sano 1997 NEJM showed slight delay in progression with 2000 IU/day in moderate Alzheimer's. Subsequent evidence mixed; not standalone Alzheimer's treatment. Specialist neurology coordination given high-dose vitamin E safety concerns from Miller meta-analysis and other trials.

• Age-Related Macular Degeneration (AREDS protocol)

  Strength of evidence for this group: modest

  AREDS antioxidant cocktail (including vitamin E 400 IU) modestly reduced AMD progression in subset analyses. AREDS2 subsequently refined formula. Specialist ophthalmology coordination; the vitamin E component is part of the cocktail rather than standalone intervention.

• NAFLD (preliminary evidence)

  Strength of evidence for this group: cautious

  PIVENS trial (NEJM 2010) showed vitamin E 800 IU/day improved liver biopsy outcomes in non-diabetic NAFLD adults. Subsequent guidelines incorporate vitamin E in selected NAFLD patients. Specialist hepatology coordination; long-term safety considerations.

• Premature infants (specialist neonatal)

  Strength of evidence for this group: cautious

  Preterm infants have low vitamin E stores and may benefit from supplementation. NICU specialist protocols. Not routine consumer pediatric supplementation.

• Healthy adults (general supplementation)

  Strength of evidence for this group: cautious

  AI is 15mg/day adult, typically met through dietary intake from vegetable oils, nuts, seeds, leafy greens. Routine supplementation in healthy non-deficient users is not warranted given Miller meta-analysis safety concerns at high doses and null prevention trial outcomes. Modest doses (100-200 IU/day natural) reasonable for users seeking AI-bridging supplementation; high-dose chronic supplementation not warranted.

• Cardiovascular disease (prevention claims)

  Strength of evidence for this group: cautious

  HOPE, Heart Protection Study, GISSI-Prevenzione subset, and other trials demonstrated null or minimal cardiovascular prevention effects. Routine high-dose vitamin E for cardiovascular prevention is not supported by current evidence. AI-level dietary intake is universally supported; therapeutic supplementation requires specialist coordination.

• Cancer prevention (general adult)

  Strength of evidence for this group: avoid

  ATBC trial demonstrated no lung cancer prevention and increased hemorrhagic stroke risk; SELECT trial demonstrated possible increased prostate cancer risk with high-dose synthetic vitamin E. Cancer prevention claims should be substantially calibrated post-SELECT; high-dose supplementation for cancer prevention in healthy users is not supported by current evidence.

• Pregnancy and lactation

  Strength of evidence for this group: cautious

  AI is 15mg/day non-pregnant adult, 19mg/day lactation, 15mg/day pregnancy. Dietary intake typically adequate; supplementation in pregnancy at very high doses has been associated with possible adverse outcomes (increased birth defect risk in some preliminary studies). Stick to AI-level intake; coordinate with OB-GYN for therapeutic supplementation.

• Anticoagulant users

  Strength of evidence for this group: cautious

  Vitamin E at higher doses has mild antiplatelet effects and may antagonize vitamin K-dependent clotting factor activity. Documented case reports of bleeding complications with high-dose vitamin E in warfarin users. Pre-surgical discontinuation 2 weeks; coordinate with anticoagulation management.

• Chemotherapy patients

  Strength of evidence for this group: cautious

  Theoretical concern about antioxidant supplementation reducing chemotherapy oxidative damage to tumor cells. Coordinate with oncology; integrative oncology consensus generally recommends caution about high-dose antioxidant supplementation during active chemotherapy.

• Vitamin C

  Interaction: synergy

  Vitamin C regenerates tocopheryl radicals back to active alpha-tocopherol through the antioxidant network. Mechanistically integrated antioxidant biology; common combination in comprehensive antioxidant supplementation. Reasonable at modest doses; caution about Bjelakovic 2007 antioxidant cocktail mortality findings at high chronic doses.

• Selenium

  Interaction: synergy

  Foundational Schwarz 1957 integrated biology, selenium-dependent glutathione peroxidases reduce lipid hydroperoxides generated despite alpha-tocopherol activity. Mechanistically inseparable. SELECT trial demonstrated combination at 200mcg selenium + 400 IU vitamin E did not produce cancer prevention; caution about chronic high-dose combination.

• Coenzyme Q10

  Interaction: synergy

  Both fat-soluble antioxidants with complementary distribution, vitamin E in membrane lipids; CoQ10 in mitochondrial inner membrane. Mechanistically integrated antioxidant network. Common combination in cardiovascular and aging supplementation.

• Omega-3 (EPA/DHA)

  Interaction: synergy

  Vitamin E protects highly unsaturated omega-3 fatty acids from peroxidation. Common combination in cardiovascular and inflammation supplementation. Mechanistically integrated lipid biology.

• Anticoagulants (Warfarin, DOACs, Antiplatelets)

  Interaction: caution

  Vitamin E at higher doses has mild antiplatelet effects and may antagonize vitamin K-dependent clotting factor activity. Documented bleeding complications with high-dose vitamin E and warfarin. Pre-surgical discontinuation 2 weeks; coordinate with anticoagulation management. Among the more clinically significant supplement-anticoagulant interactions.

• Vitamin K

  Interaction: caution

  High-dose vitamin E (>400 IU/day) can antagonize vitamin K-dependent clotting factor activity. Modest doses generally well-tolerated; high-dose chronic supplementation warrants vitamin K adequacy consideration.

• Statins

  Interaction: caution

  Mixed evidence for vitamin E-statin interactions. HATS trial (Cheung 2001) suggested antioxidant cocktail (vitamin E + C + beta-carotene + selenium) attenuated simvastatin-niacin HDL-raising effects. Modest clinical relevance; coordinate with cardiology.

• Chemotherapy Agents

  Interaction: caution

  Theoretical antioxidant interference with chemotherapy oxidative damage mechanisms. Integrative oncology consensus generally recommends caution about high-dose vitamin E during active chemotherapy. Coordinate with oncology.

• Iron Supplements

  Interaction: caution

  Iron can promote lipid peroxidation; vitamin E provides protection. Mechanistic synergy but no specific supplementation timing requirement.

• Beta-Carotene

  Interaction: caution

  ATBC trial combination (alpha-tocopherol 50mg + beta-carotene 20mg in Finnish smokers) demonstrated increased lung cancer with beta-carotene; vitamin E component showed null or modest negative effects. Avoid high-dose combination supplementation particularly in smokers.

Look for: specific vitamin E form disclosed (d-alpha-tocopherol natural preferred over dl-alpha synthetic); explicit IU and mg content per serving; mixed tocopherol or tocotrienol specification if pursuing comprehensive vitamin E family supplementation; annatto-derived specification for alpha-tocopherol-free tocotrienol products; USP or NSF third-party verification; reputable manufacturer with quality control disclosure. Avoid: products without specific form disclosure (likely dl-alpha synthetic by default); very high-dose products (>400 IU/day) without specific clinical indication and specialist coordination given Miller meta-analysis safety concerns; products marketed with aggressive cancer or cardiovascular prevention claims that exceed current evidence base; products from manufacturers without third-party testing disclosure; combination products that obscure individual vitamin E dose toward UL.

Vitamin E's discovery came in 1922 through Herbert McLean Evans and Katharine Scott Bishop at UC Berkeley, characterizing "factor X" required for rat reproductive function in dietary studies. The name tocopherol from Greek tokos ("childbirth") + phero ("to bear") reflects the original fertility-factor characterization. Alpha-tocopherol structure was characterized in 1938 through Erhard Fernholz at the Mellon Institute; synthesis followed shortly. The discovery of the broader vitamin E family (beta-, gamma-, delta-tocopherols, and tocotrienols) developed through subsequent decades, substantially expanding understanding of vitamin E biology. The modern essentiality era developed through human nutrition research in the 1950s-1970s. The Schwarz 1957 selenium-vitamin E integrated biology characterization established the foundational antioxidant nutrition framework. The early establishment of RDA values, recognition of fat-soluble vitamin absorption requirements, and characterization of deficiency syndromes (rare in healthy populations) developed through this era. The major clinical trial era began in the 1990s with substantial expectations about vitamin E for cardiovascular and cancer prevention based on mechanistic plausibility and observational epidemiology. The ATBC trial (1994 NEJM) in Finnish smokers was the foundational large-scale prevention trial, substantially negative outcomes including no lung cancer prevention and increased hemorrhagic stroke risk. The CHAOS trial (1996 Lancet) showed initial positive cardiovascular results in established CHD patients that subsequent larger trials did not replicate. The HOPE trial (2000 NEJM) in 9,541 high-risk users demonstrated no cardiovascular protective effect of vitamin E 400 IU/day. The Heart Protection Study (2002 Lancet) confirmed null cardiovascular outcomes in 20,536 high-risk users. GISSI-Prevenzione (1999 Lancet) showed modest mixed cardiovascular results. The cumulative cardiovascular evidence substantially recalibrated expectations about high-dose vitamin E for cardiovascular prevention. The Sano 1997 NEJM Alzheimer's disease trial showed slight progression delay at 2000 IU/day in moderate Alzheimer's disease, among the more positive specific clinical findings, though subsequent evidence has been mixed. The AREDS trial (2001) demonstrated antioxidant cocktail (including vitamin E 400 IU) modest macular degeneration progression reduction; AREDS2 subsequently refined the formula. The Miller 2005 Annals of Internal Medicine meta-analysis demonstrated possible increased all-cause mortality with chronic vitamin E supplementation >400 IU/day. The Bjelakovic 2007 JAMA Cochrane systematic review extended this concern to broader antioxidant supplementation contexts. These meta-analyses substantially recalibrated safety expectations about high-dose vitamin E. The SELECT trial (2009 JAMA) was the foundational mechanism-translation failure example. The trial in 35,000+ men randomized to vitamin E 400 IU/day, selenium 200mcg/day, both, or placebo for prostate cancer prevention. The trial was halted early for futility and concerning signals: no prostate cancer prevention; vitamin E alone showed possible increased prostate cancer risk (RR 1.17); selenium showed possible increased diabetes risk. The cumulative SELECT, ATBC, Miller, Bjelakovic, and other negative evidence substantially recalibrated vitamin E clinical positioning toward AI-level dietary intake rather than high-dose pharmacological supplementation. The PIVENS trial (2010 NEJM) provided some positive specific evidence, vitamin E 800 IU/day improved liver biopsy outcomes in non-diabetic NAFLD adults, supporting incorporation into selected NAFLD treatment protocols under hepatology coordination. The annatto-derived tocotrienol category has emerged through the 2010s-2020s with EVNol (Excelvite) and other manufacturers providing alpha-tocopherol-free tocotrienol supplementation. Preliminary cardiovascular and neuroprotective evidence continues to develop; mainstream clinical positioning remains research-grade rather than guideline-integrated. The modern consumer market has substantially recalibrated through the 2010s-2020s reflecting the negative prevention trial evidence. Mass-market high-dose vitamin E (400-1000 IU) products have declined in favor of modest doses (100-200 IU) and mixed tocopherol products. The "antioxidant for cardiovascular prevention" consumer framing has substantially diminished; AI-level dietary adequacy framing has gained ground.

1. 1922Evans and Bishop discover vitamin E (factor X) at UC Berkeley
2. 1938Fernholz characterizes alpha-tocopherol structure
3. 1957Schwarz characterizes selenium-vitamin E integrated biology
4. 1986Burton and Ingold definitive mechanism characterization (NRC Canada)
5. 1994ATBC trial Finnish smokers (NEJM), null lung cancer, increased hemorrhagic stroke
6. 1996CHAOS trial Lancet, initial CHD enthusiasm
7. 1997Sano Alzheimer's NEJM, slight progression delay
8. 1999GISSI-Prevenzione Lancet, mixed cardiovascular
9. 2000HOPE NEJM, null cardiovascular prevention
10. 2001AREDS macular degeneration cocktail
11. 2002Heart Protection Study Lancet, null cardiovascular
12. 2005Miller meta-analysis Ann Intern Med, mortality signal at high doses
13. 2007Bjelakovic JAMA Cochrane antioxidant mortality meta-analysis
14. 2009SELECT trial JAMA, possible prostate cancer signal at 400 IU
15. 2010PIVENS NEJM, NAFLD positive evidence at 800 IU
16. 2010s-2020sAnnatto tocotrienol category emergence; consumer market recalibration

• Whether mixed tocopherol supplementation produces clinically meaningful advantages over alpha-tocopherol alone in head-to-head trials, preliminary evidence is suggestive but rigorous comparison limited.
• Whether annatto-derived tocotrienol supplementation will mature into established clinical applications (cardiovascular, neuroprotective) or remain specialty research-grade product.
• Whether genetic variants in alpha-TTP, tocopherol metabolism enzymes, or vitamin E transport produce individual variability in optimal vitamin E intake.
• Whether the SELECT trial prostate cancer signal generalizes across vitamin E forms or is specific to synthetic dl-alpha-tocopherol at 400 IU/day.
• Whether vitamin E has specific applications in age-related cognitive decline, Alzheimer's disease, or other neurodegenerative conditions beyond the modest Sano 1997 evidence.
• Whether the NAFLD evidence (PIVENS 2010) will mature into broader hepatology guideline integration, current use is limited to specific patient subgroups.
• Whether the integrated antioxidant biology with selenium and vitamin C should inform specific clinical supplementation protocols beyond AI-level intake from dietary sources.
• Whether vitamin E has specific applications in skin aging and dermatologic conditions beyond traditional cosmetic and barrier-protective applications.

Universally available globally as dietary supplement, food fortification, and pharmaceutical preparations. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Pharmaceutical preparations: some prescription vitamin E formulations available for specific clinical applications (NAFLD, cystic fibrosis, abetalipoproteinemia, AVED). Major retail supplement brands include NOW Foods, Pure Encapsulations, Thorne, Designs for Health, Solgar, Nature's Way, Nature Made, Doctor's Best, Life Extension, and most multivitamin manufacturers. The d-alpha-tocopherol natural form is widely available; dl-alpha-tocopherol synthetic form remains in many mass-market multivitamins for cost reasons. Mixed tocopherol products are available from specialty brands. Annatto-derived tocotrienol products are available from EVNol (Excelvite) and similar specialty manufacturers. Whole food sources (wheat germ oil, sunflower seeds, almonds, leafy greens) are universally available. Production of synthetic dl-alpha-tocopherol is dominated by DSM, BASF, and other large industrial chemical manufacturers; natural d-alpha-tocopherol is produced from vegetable oil distillation (soy, sunflower) with substantial commercial supply. Tocotrienol production from annatto involves specialized chemistry from Bixa orellana seeds, predominantly Malaysian/Indonesian sources. Quality variation across brands is modest given the well-established chemistry; third-party testing (USP, NSF) provides standard quality assurance. The form distinction (d-alpha vs dl-alpha) and family composition (alpha alone vs mixed tocopherols vs tocotrienols) matter more than typical brand quality differences for clinical applications.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Class

Essential fat-soluble vitamin family (8 forms)

Discovery

1922 (Evans and Bishop, UC Berkeley)

Greek name origin

Tokos (childbirth) + phero (to bear)

Family members

4 tocopherols (alpha, beta, gamma, delta), 4 tocotrienols (alpha, beta, gamma, delta)

Dominant supplemented form

Alpha-tocopherol (d- natural, dl- synthetic)

Adult AI

15mg/day (22 IU natural)

What follows is unfinished work on our side, not a finding about Vitamin E. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.